Hepatitis C virus specific antibody
The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.
1. A synthetic or recombinant antibody or an antigen binding fragment thereof that specifically binds HCV E2 or HCV E1E2, comprising the CDR sequences of:
SEQ ID NOs 1, 6, 11, 16, 21 and 26;
SEQ ID NOs 2, 7, 12, 17, 22 and 27;
SEQ ID NOs 3, 8, 13, 18, 23 and 28;
SEQ ID NOs 4, 9, 14, 19, 24 and 29;
SEQ ID NOs 5, 10, 15, 20, 25 and 30;
SEQ ID NOs 81, 85, 89, 93, 97 and 101;
SEQ ID NOs 82, 86, 90, 94, 98 and 102;
SEQ ID NOs 83, 87, 91, 95, 99 and 103; or
SEQ ID NOs 84, 88, 92, 96, 100 and 104.
2. The antibody or antigen binding fragment thereof of claim 1 , further comprising at least one of:
a heavy chain variable region sequence comprising a sequence which has at least 80% sequence identity with a sequence selected from the group consisting of SEQ ID NOs:31-35 and SEQ ID NOs 105-108; or
a light chain variable region sequence which has at least 80% sequence identity with a sequence selected from the group consisting of SEQ ID NOs:36-40 and SEQ ID NOs: 109-112.
3. The antibody or antigen binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof specifically binds to an epitope of hepatitis C virus (HCV) protein E2, said epitope comprising amino acids corresponding to amino acids F442, Y527, W529, G530, D535 and W616 of the H77 E2 amino acid sequence (SEQ ID NO: 145), and wherein said antibody or antigen binding fragment thereof inhibits binding of HCV protein E1E2 to CD81.
4. A method of treating an HCV infection in a patient in need thereof, comprising administering a synthetic or recombinant antibody, or an antigen binding fragment thereof according to claim 1 , to said patient.
5. A method for determining whether an individual is suffering from a HCV infection, comprising:
contacting a sample from said individual with the antibody or antigen binding fragment thereof of claim 1 and
allowing said antibody or antigen binding fragment thereof to bind HCV, if present, and
determining whether or not HCV is bound to said antibody or antigen binding fragment thereof, thereby determining whether or nor said individual is suffering from HCV infection.
6. A method of inhibiting binding of HCV protein E1E2 to CD81 comprising:
administering to a patient a synthetic or recombinant antibody, or an antigen binding fragment thereof, according to claim 1 .
7. A method for producing the antibody or an antigen binding fragment thereof of claim 1 , the method comprising:
providing a cell with a nucleic acid molecule or a vector, said nucleic acid molecule or vector comprising sequences encoding the CDRs of the antibody or antigen binding fragment thereof of claim 1 ;
allowing said cell to translate the nucleic acid sequence comprised by said nucleic acid molecule or vector, thereby producing said antibody or antigen binding fragment thereof of claim 1 ;
harvesting, purifying and/or isolating said antibody or antigen binding fragment thereof of claim 1 .